chronic urticaria. Other urticaria
Conditions
Interventions
Intervention 1: Intervention group: will receive Cetirizine 10mg PO BiD for two weeks and Tranexamic Acid 500mg PO Q6h for two weeks. Intervention 2: Control group: will receive Cetirizine 10mg PO BiD
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients older than 12 years old Patients with spontaneous chronic urticaria, according to the criteria of the European Academy of Allergology and Clinical Immunology (EAACI) in agreement with the European Dermatology Forum (EDF), and the World Allergy Organization (WAO), corresponding to an association of the following symptoms: urticarial eruptions and/or recurrent angioedema for at least 6 weeks
Exclusion criteria
Exclusion criteria: Urticaria associated with a specific systematic disease including cutaneous and systemic mastocytosis Urticarial vasculitis Autoinflammatory diseases associated with cryopyrin Bradykinin angioedema Isolated angioedema whose origin is not clearly attributable to spontaneous chronic urticaria Presence of a contraindication to Tranexamic Acid and to Cetirizine such as any history of thromboembolic events as pulmonary thromboembolism and deep vein thrombosis Coagulopathy. Unwillingness of the patients or their legal guardians to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chronic Urticaria Quality of Life. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: CU-QoL questionnaire.;Severity of Chronic Urticaria. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: UAS7 questionnaire.;Level of D-dimer. Timepoint: before intervention and 2 weeks after intervention. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAida Askarisarvestani
Shiraz University of Medical Sciences
Outcome results
None listed